Signs and symptoms of HIV/AIDS
The stages of HIV infection are acute infection (also known as primary infection), latency and AIDS. Acute infection lasts for several weeks and may include symptoms such as fever, swollen lymph nodes, inflammation of the throat, rash, muscle pain, malaise, and mouth and esophageal sores. The latency stage involves few or no symptoms and can last anywhere from two weeks to twenty years or more, depending on the individual. AIDS, the final stage of HIV infection, is defined by low CD4+ T cell counts (fewer than 200 per μL), various opportunistic infections, cancers and other conditions.
Acute HIV infection, primary HIV infection or acute seroconversion syndrome:416 is the second stage of HIV infection. It occurs after the incubation stage, before the latency stage and the potential AIDS succeeding the latency stage.
During this period (usually days to weeks post-exposure) fifty to ninety percent of infected individuals develop an influenza or mononucleosis-like illness called acute HIV infection (or HIV prodrome), the most common symptoms of which may include fever, lymphadenopathy, pharyngitis, rash, myalgia, malaise, mouth and esophageal sores, and may also include, but less commonly, headache, nausea and vomiting, fatigue, ulcers in the mouth or on the genitals, enlarged liver/spleen, weight loss, thrush, night sweats and diarrhea and neurological symptoms. Infected individuals may experience all, some, or none of these symptoms. The duration of symptoms varies, averaging 28 days and usually lasts at least a week.
Because of the nonspecific nature of these symptoms, they are often not recognized as signs of HIV infection. Even if patients go to their doctors or a hospital, they will often be misdiagnosed as having one of the more common infectious diseases with the same symptoms. As a consequence, these primary symptoms are not used to diagnose HIV infection, as they do not develop in all cases and because many are caused by other more common diseases. However, recognizing the syndrome can be important because the patient is much more infectious during this period.
A strong immune defense reduces the number of viral particles in the blood stream, marking the start of secondary or chronic HIV infection. The secondary stage of HIV infection can vary between two weeks and 10 years. During the secondary phase of infection, HIV is active within lymph nodes, which typically become persistently swollen, in response to large amounts of virus that become trapped in the follicular dendritic cells (FDC) network. The surrounding tissues that are rich in CD4+ T cells may also become infected, and viral particles accumulate both in infected cells and as free virus. Individuals who are in this phase are still infectious. During this time, CD4+ CD45RO+ T cells carry most of the proviral load. A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable viral load and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable viral load without anti-retroviral treatment are known as elite controllers or elite suppressors (ES).
The symptoms of AIDS are primarily the result of conditions that do not normally develop in individuals with healthy immune systems. Most of these conditions are opportunistic infections caused by bacteria, viruses, fungi and parasites that are normally controlled by the elements of the immune system that HIV damages. These infections affect nearly every organ system.
People with AIDS also have an increased risk of developing various cancers such as Kaposi's sarcoma, cervical cancer and cancers of the immune system known as lymphomas. Additionally, people with AIDS often have systemic symptoms of infection like fevers, sweats (particularly at night), swollen glands, chills, weakness, and weight loss. The specific opportunistic infections that AIDS patients develop depend in part on the prevalence of these infections in the geographic area in which the patient lives.
Pneumocystis pneumonia (PCP) (originally known as Pneumocystis carinii pneumonia) is relatively rare in healthy, immunocompetent people, but common among HIV-infected individuals. It is caused by Pneumocystis jirovecii.
Before the advent of effective diagnosis, treatment and routine prophylaxis in Western countries, it was a common immediate cause of death. In developing countries, it is still one of the first indications of AIDS in untested individuals, although it does not generally occur unless the CD4 count is less than 200 cells per µL of blood.
Tuberculosis (TB) is unique among infections associated with HIV because it is transmissible to immunocompetent people via the respiratory route, and is not easily treatable once identified. Multidrug resistance is a serious problem. Tuberculosis with HIV co-infection (TB/HIV) is a major world health problem according to the World Health Organization: in 2007, 456,000 deaths among incident TB cases were HIV-positive, a third of all TB deaths and nearly a quarter of the estimated 2 million HIV deaths in that year. Even though its incidence has declined because of the use of directly observed therapy and other improved practices in Western countries, this is not the case in developing countries where HIV is most prevalent. In early-stage HIV infection (CD4 count >300 cells per µL), TB typically presents as a pulmonary disease. In advanced HIV infection, TB often presents atypically with extrapulmonary (systemic) disease a common feature. Symptoms are usually constitutional and are not localized to one particular site, often affecting bone marrow, bone, urinary and gastrointestinal tracts, liver, regional lymph nodes, and the central nervous system.
Esophagitis is an inflammation of the lining of the lower end of the esophagus (gullet or swallowing tube leading to the stomach). In HIV-infected individuals, this is normally due to fungal (candidiasis) or viral (herpes simplex-1 or cytomegalovirus) infections. In rare cases, it could be due to mycobacteria.
Unexplained chronic diarrhea in HIV infection is due to many possible causes, including common bacterial (Salmonella, Shigella, Listeria or Campylobacter) and parasitic infections; and uncommon opportunistic infections such as cryptosporidiosis, microsporidiosis, Mycobacterium avium complex (MAC) and viruses, astrovirus, adenovirus, rotavirus and cytomegalovirus, (the latter as a course of colitis).
In some cases, diarrhea may be a side effect of several drugs used to treat HIV, or it may simply accompany HIV infection, particularly during primary HIV infection. It may also be a side effect of antibiotics used to treat bacterial causes of diarrhea (common for Clostridium difficile). In the later stages of HIV infection, diarrhea is thought to be a reflection of changes in the way the intestinal tract absorbs nutrients, and may be an important component of HIV-related wasting.
Neurological and psychiatric
Toxoplasmosis is a disease caused by the single-celled parasite called Toxoplasma gondii; it usually infects the brain, causing toxoplasma encephalitis, but it can also infect and cause disease in the eyes and lungs. Cryptococcal meningitis is an infection of the meninx (the membrane covering the brain and spinal cord) by the fungus Cryptococcus neoformans. It can cause fevers, headache, fatigue, nausea, and vomiting. Patients may also develop seizures and confusion; left untreated, it can be lethal.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease, in which the gradual destruction of the myelin sheath covering the axons of nerve cells impairs the transmission of nerve impulses. It is caused by a virus called JC virus which occurs in 70% of the population in latent form, causing disease only when the immune system has been severely weakened, as is the case for AIDS patients. It progresses rapidly, usually causing death within months of diagnosis.
HIV-associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of HIV infected brain macrophages and microglia. These cells are productively infected by HIV and secrete neurotoxins of both host and viral origin. Specific neurological impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and are associated with low CD4+ T cell levels and high plasma viral loads.
Prevalence is 10–20% in Western countries but only 1–2% of HIV infections in India. This difference is possibly due to the HIV subtype in India. AIDS related mania is sometimes seen in patients with advanced HIV illness; it presents with more irritability and cognitive impairment and less euphoria than a manic episode associated with true bipolar disorder. Unlike the latter condition, it may have a more chronic course. This syndrome is less frequently seen with the advent of multi-drug therapy.
People with HIV infections have substantially increased incidence of several cancers. This is primarily due to co-infection with an oncogenic DNA virus, especially Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV) (also known as human herpesvirus-8 [HHV-8]), and human papillomavirus (HPV).
Kaposi's sarcoma (KS) is the most common tumor in HIV-infected patients. The appearance of this tumor in young homosexual men in 1981 was one of the first signals of the AIDS epidemic. Caused by a gammaherpes virus called Kaposi's sarcoma-associated herpes virus (KSHV), it often appears as purplish nodules on the skin, but can affect other organs, especially the mouth, gastrointestinal tract, and lungs. High-grade B cell lymphomas such as Burkitt's lymphoma, Burkitt's-like lymphoma, diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma present more often in HIV-infected patients. These particular cancers often foreshadow a poor prognosis. Epstein-Barr virus (EBV) or KSHV cause many of these lymphomas. In HIV-infected patients, lymphoma often arises in extranodal sites such as the gastrointestinal tract. When they occur in an HIV-infected patient, KS and aggressive B cell lymphomas confer a diagnosis of AIDS.
In addition to the AIDS-defining tumors listed above, HIV-infected patients are at increased risk of certain other tumors, notably Hodgkin's disease, anal and rectal carcinomas, hepatocellular carcinomas, head and neck cancers, and lung cancer. Some of these are causes by viruses, such as Hodgkin's disease (EBV), anal/rectal cancers (HPV), head and neck cancers (HPV), and hepatocellular carcinoma (hepatitis B or C). Other contributing factors include exposure to carcinogens (cigarette smoke for lung cancer), or living for years with subtle immune defects.
The incidence of many common tumors, such as breast cancer or colon cancer, does not increase in HIV-infected patients. In areas where HAART is extensively used to treat AIDS, the incidence of many AIDS-related malignancies has decreased, but at the same time malignant cancers overall have become the most common cause of death of HIV-infected patients. In recent years, an increasing proportion of these deaths have been from non-AIDS-defining cancers.
In line with the treatment of cancer, chemotherapy has shown promise in increasing the number of uninfected T-cells and diminishing the viral load.
People with AIDS often develop opportunistic infections that present with non-specific symptoms, especially low-grade fevers and weight loss. These include opportunistic infection with Mycobacterium avium-intracellulare and cytomegalovirus (CMV). CMV can cause colitis, as described above, and CMV retinitis can cause blindness.
Talaromycosis due to Talaromyces marneffei is now the third most common opportunistic infection (after extrapulmonary tuberculosis and cryptococcosis) in HIV-positive individuals within the endemic area of Southeast Asia.
An infection that often goes unrecognized in people with AIDS is Parvovirus B19. Its main consequence is anemia, which is difficult to distinguish from the effects of antiretroviral drugs used to treat AIDS itself.
- James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
- BARBARA LEE PERLMUTTER, M.D., PH.D., JORDAN B. GLASER, M.D., and SAMWEL O. OYUGI, M.D. (1 August 1999). "How to Recognize and Treat Acute HIV Syndrome". American Family Physician. 60 (2): 535–542. PMID 10465228. Retrieved 30 August 2016.
It is now known that 50 to 90 percent of patients acutely infected with HIV experience at least some symptoms of the acute retroviral syndrome.CS1 maint: multiple names: authors list (link)
- Lisa B. Hightow-Weidman, Carol E. Golin, Kelly Green, Eva N. P. Shaw, Pia D. M. MacDonald, Peter A. Leone (2009). "Identifying People with Acute HIV Infection: Demographic Features, Risk Factors, and Use of Health Care among Individuals with AHI in North Carolina". AIDS and Behavior. 13 (6): 1075–1083. doi:10.1007/s10461-008-9519-5. ISSN 1090-7165. PMC 2787774. PMID 19127422.
Seventy-five percent experienced symptoms consistent with acute retroviral syndrome; although 83% sought medical care for these symptoms, only 15% were appropriately diagnosed at that initial medical visit, suggesting opportunities to diagnose these individuals earlier were missed.CS1 maint: uses authors parameter (link)
- "Early signs of HIV in men & women".
- Kahn, J. O.; Walker, B. D. (1998). "Acute Human Immunodeficiency Virus type 1 infection". N. Engl. J. Med. 339 (1): 33–39. doi:10.1056/NEJM199807023390107. PMID 9647878.
- Daar ES, Little S, Pitt J, et al. (2001). "Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. S2CID 34714025.
- Burton GF, Keele BF, Estes JD, Thacker TC, Gartner S (2002). "Follicular dendritic cell contributions to HIV pathogenesis". Semin Immunol. 14 (4): 275–284. CiteSeerX 10.1.1.364.8696. doi:10.1016/S1044-5323(02)00060-X. PMID 12163303.
- Clapham PR, McKnight A (2001). "HIV-1 receptors and cell tropism". Br. Med. Bull. 58 (4): 43–59. doi:10.1093/bmb/58.1.43. PMID 11714623.
- Grabar, S., Selinger-Leneman, H., Abgrall, S., Pialoux, G., Weiss, L., Costagliola, D. (2009). "Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV". AIDS. 23 (9): 1163–1169. doi:10.1097/QAD.0b013e32832b44c8. PMID 19444075. S2CID 27256348.CS1 maint: multiple names: authors list (link)
- Blankson, J. N. (2010). "Control of HIV-1 replication in elite suppressors". Discovery Medicine. 9 (46): 261–266. PMID 20350494.
- Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA (2003). "Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa". Clin. Infect. Dis. 36 (5): 656–662. doi:10.1086/367655. PMID 12594648.
- Bruno G, Saracino A, Monno L, Angarano G (2017). "The Revival of an "Old" Marker: CD4/CD8 Ratio". AIDS Reviews. 19 (2): 81–88. PMID 28182620.
- Guss DA (1994). "The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1". J. Emerg. Med. 12 (3): 375–384. doi:10.1016/0736-4679(94)90281-X. PMID 8040596.
- Guss DA (1994). "The acquired immune deficiency syndrome: an overview for the emergency physician, Part 2". J. Emerg. Med. 12 (4): 491–497. doi:10.1016/0736-4679(94)90346-8. PMID 7963396.
- Huang, L; Cattamanchi, A; Davis, JL; den Boon, S; Kovacs, J; Meshnick, S; Miller, RF; Walzer, PD; Worodria, W; Masur, H; International HIV-associated Opportunistic Pneumonias (IHOP) Study; Lung HIV, Study (June 2011). "HIV-associated Pneumocystis pneumonia". Proceedings of the American Thoracic Society. 8 (3): 294–300. doi:10.1513/pats.201009-062WR. PMC 3132788. PMID 21653531.
- Feldman C (2005). "Pneumonia associated with HIV infection". Current Opinion in Infectious Diseases. 18 (2): 165–170. doi:10.1097/01.qco.0000160907.79437.5a. PMID 15735422. S2CID 31827307.
- Kwara A, Ramachandran G, Swaminathan S (January 2010). "Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all". Expert Opinion on Drug Metabolism & Toxicology. 6 (1): 55–68. doi:10.1517/17425250903393752. PMC 2939445. PMID 19968575.
- "Global Tuberculosis Control 2009" (PDF). Archived from the original (PDF) on January 27, 2012. Retrieved November 1, 2011.
- Decker CF, Lazarus A (August 2000). "Tuberculosis and HIV infection. How to safely treat both disorders concurrently". Postgraduate Medicine. 108 (2): 57–60, 65–8. doi:10.3810/pgm.2000.08.1181. PMID 10951746. S2CID 213057.
- Zaidi SA, Cervia JS (2002). "Diagnosis and management of infectious esophagitis associated with human immunodeficiency virus infection". Journal of the International Association of Physicians in AIDS Care. 1 (2): 53–62. doi:10.1177/154510970200100204. PMID 12942677. S2CID 38823534.
- Pollok RC (2001). "Viruses causing diarrhoea in AIDS". Novartis Foundation Symposium. Novartis Foundation Symposia. 238: 276–83, discussion 283–8. doi:10.1002/0470846534.ch17. ISBN 978-0-470-84653-7. PMID 11444032.
- Guerrant RL, Hughes JM, Lima NL, Crane J (1990). "Diarrhea in developed and developing countries: magnitude, special settings, and etiologies". Reviews of Infectious Diseases. 12 (Suppl 1): S41–50. doi:10.1093/clinids/12.Supplement_1.S41. PMC 7792920. PMID 2406855.
- Gazzard, B; Balkin, A; Hill, A (2010). "Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review". AIDS Reviews. 12 (2): 67–75. PMID 20571601.
- Luft BJ, Chua A (August 2000). "Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy". Current Infectious Disease Reports. 2 (4): 358–362. doi:10.1007/s11908-000-0016-x. PMID 11095878. S2CID 30642847.
- Sadler M, Nelson MR (June 1997). "Progressive multifocal leukoencephalopathy in HIV". International Journal of STD & AIDS. 8 (6): 351–7. doi:10.1258/0956462971920181. PMID 9179644.
- Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C (2001). "Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments". Clinical Neuropathology. 20 (4): 146–55. PMID 11495003.
- Grant I, Sacktor H, McArthur J (2005). "HIV neurocognitive disorders" (PDF). In H.E. Gendelman, I. Grant, I. Everall, S. A. Lipton, S. Swindells. (eds.). The Neurology of AIDS (2nd ed.). London, UK: Oxford University Press. pp. 357–373. ISBN 978-0-19-852610-0.
- Satishchandra P, Nalini A, Gourie-Devi M, et al. (January 2000). "Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989–96)". The Indian Journal of Medical Research. 111: 14–23. PMID 10793489.
- Wadia RS, Pujari SN, Kothari S, et al. (March 2001). "Neurological manifestations of HIV disease". The Journal of the Association of Physicians of India. 49: 343–8. PMID 11291974.
- Boshoff C, Weiss R (2002). "AIDS-related malignancies". Nature Reviews Cancer. 2 (5): 373–382. doi:10.1038/nrc797. PMID 12044013. S2CID 13513517.
- Yarchoan R, Tosato G, Little RF (2005). "Therapy insight: AIDS-related malignancies – the influence of antiviral therapy on pathogenesis and management". Nat. Clin. Pract. Oncol. 2 (8): 406–415. doi:10.1038/ncponc0253. PMID 16130937. S2CID 23476060.
- Ho-Yen C, Chang F (June 1, 2008). "Gastrointestinal Malignancies in HIV/AIDS". The AIDS Reader. 18 (6).
- Palefsky J (2007). "Human papillomavirus infection in HIV-infected persons". Top HIV Med. 15 (4): 130–3. PMID 17720998.
- Bonnet F, Lewden C, May T, et al. (2004). "Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy". Cancer. 101 (2): 317–324. doi:10.1002/cncr.20354. PMID 15241829. S2CID 79554735.
- Karrakchou, J., Rachik, M., & Gourari, S. (2006). Optimal control and infectiology: Application to an HIV/AIDS model. Applied Mathematics and Computation, 177(2), 807–818. doi: 10.1016/j.amc.2005.11.092
- Skoulidis, F; Morgan, MS; MacLeod, KM (August 2004). "Penicillium marneffei: a pathogen on our doorstep?". Journal of the Royal Society of Medicine. 97 (8): 394–6. doi:10.1258/jrsm.97.8.394. PMC 1079563. PMID 15286196.
- Silvero AM; Acevedo-Gadea CR; Pantanowitz L "" (June 4, 2009). "Unsuspected Parvovirus B19 Infection in a Person With AIDS". The AIDS Reader. 19 (6).
- Presence of symptom as a predictor of acute HIV infection.
- Absence of symptom as a predictor of no acute HIV infection.